ZyVersa Therapeutics, Inc. (ZVSA)
USD 0.7
(-7.64%)
USD 0.7
(-7.64%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Cost of Revenue | 10.4 Thousand | 10.4 Thousand | 10.4 Thousand | 10.4 Thousand |
| Gross Profit | -10.4 Thousand | -10.4 Thousand | -10.4 Thousand | -10.4 Thousand |
| Operating Expenses | 14.41 Million | 13.01 Million | 7.7 Million | 11.83 Million |
| Selling, General and Administrative Expenses | 11.2 Million | 7.6 Million | 5.58 Million | 5.36 Million |
| Research and Development Expenses | 3.2 Million | 5.4 Million | 2.12 Million | 6.46 Million |
| Other Expenses | - | - | - | - |
| Cost and Expenses | 14.42 Million | 13.01 Million | 7.7 Million | 11.83 Million |
| Operating Income | -14.42 Million | -13.01 Million | -7.7 Million | -11.83 Million |
| Interest Expense | -457 Thousand | 427.54 Thousand | 821.36 Thousand | 516.45 Thousand |
| Income Tax Expense | -9.45 Million | 745.05 Million | 821.36 Thousand | 516.45 Thousand |
| Earnings before Tax | -107.75 Million | -14.04 Million | -8.08 Million | -12.68 Million |
| Net Income | -98.29 Million | -759.09 Million | -8.9 Million | -13.19 Million |
| Earnings Per Share Basic | -1089.67 | -930.25 | -173.66 | -272.45 |
| Earnings Per Share Diluted | -1089.67 | -930.25 | -173.66 | -272.45 |
| Weighted Average Shares Outstanding | 97.5 Thousand | 25.94 Thousand | 46.55 Thousand | 46.55 Thousand |
| Weighted Average Shares Outstanding (Diluted) | 97.5 Thousand | 25.94 Thousand | 46.55 Thousand | 46.55 Thousand |
| Gross Margin | - | - | - | - |
| EBIT Margin | - | - | - | - |
| Profit Margin | - | - | - | - |
| EBITDA | -107.74 Million | -11.67 Million | -7.25 Million | -12.15 Million |
| Earnings Before Tax Margin | - | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 15.6 Thousand | - | - | - |
| Cost of Revenue | 2600.00 | 10.43 Thousand | 2600.00 | 10.4 Thousand | 2600.00 | 2600.00 |
| Gross Profit | -2600.00 | -10.43 Thousand | 13 Thousand | -10.4 Thousand | -2600.00 | -2600.00 |
| Operating Expenses | 2.75 Million | 2.81 Million | 1.77 Million | 14.41 Million | 2.9 Million | 5.14 Million |
| Selling, General and Administrative Expenses | 2.04 Million | 2.3 Million | 1.51 Million | - | 2.22 Million | 3.92 Million |
| Research and Development Expenses | 709.04 Thousand | 512.93 Thousand | 257.11 Thousand | - | 673.94 Thousand | 1.22 Million |
| Other Expenses | - | - | 93.25 Billion | 93.33 Billion | - | 81.17 Million |
| Cost and Expenses | 2.75 Million | 2.82 Million | 1.77 Million | 14.42 Million | 2.9 Million | 5.14 Million |
| Operating Income | -2.75 Million | -2.82 Million | -1.77 Million | -14.42 Million | -2.9 Million | -86.32 Million |
| Interest Expense | 58 Thousand | 101.00 | -456.44 Thousand | -457 Thousand | 210.00 | 314.00 |
| Income Tax Expense | 9707.00 | 1.00 | -596.06 Thousand | -9.45 Million | -485.00 | -7.81 Million |
| Earnings before Tax | -2.75 Million | -2.82 Million | -13.93 Million | -107.75 Million | -2.9 Million | -86.32 Million |
| Net Income | -2.76 Million | -2.82 Million | -13.33 Million | -98.29 Million | -2.9 Million | -78.51 Million |
| Earnings Per Share Basic | -3.31 | -4.53 | -3.29 | - | -3.28 | -153.90 |
| Earnings Per Share Diluted | -3.31 | -4.53 | -3.29 | - | -3.28 | -153.90 |
| Weighted Average Shares Outstanding | 834.91 Thousand | 623.6 Thousand | 4.05 Million | 97.5 Thousand | 885.1 Thousand | 510.16 Thousand |
| Weighted Average Shares Outstanding (Diluted) | 834.91 Thousand | 623.6 Thousand | 4.05 Million | 97.5 Thousand | 885.1 Thousand | 510.16 Thousand |
| Gross Margin | - | - | 0.83 | - | - | - |
| EBIT Margin | - | - | -113.69 | - | - | - |
| Profit Margin | - | - | -855.03 | - | - | - |
| EBITDA | -2.75 Million | -2.81 Million | -1.77 Million | - | -2.9 Million | 76.02 Million |
| Earnings Before Tax Margin | - | - | -113.86 | - | - | - |
VSEE
IDKOY
GVR
FFNT
MALEE
FEMY